SlideShare a Scribd company logo
1 of 28
Post-market: recalls and non-recall actions
Speakers ―
Simon Waters
Recalls Unit, Therapeutic Goods Administration
Hugh Cameron
Director Regulatory Affairs ANZ, Becton Dickinson
Post-market
Recalls and non-recall actions
Simon Waters
Recalls Unit
Manufacturing Quality Branch
Devices Sponsor Information Day 2015
15 October 2015
The URPTG
(current) 2004 edition
Available online at
http://www.tga.gov.au/pu
blication/uniform-recall-
procedure-therapeutic-
goods-urptg
Post-market - Recalls and non-recall actions 2
Revised URPTG - proposed changes
• Web based format – easy to navigate
• Step-by-step protocol with supporting information
• New/changes to recall terminologies
• Risk classification – inclusion of probability aspects
• Greater clarification on the requirements for medical
devices (including IVDs)
• Refined information required to assess a recall action
Feedback from the public consultation will be considered
before finalising the changes
Post-market - Recalls and non-recall actions 3
Recall actions – proposed changes
The proposal is to have four types of recall actions:
• Recall – the permanent removal of deficient goods from the market
or from use
• Recall for Product Defect Correction – repair, modification,
adjustment, re-labelling, update to instructions or labelling
• Hazard Alert – providing information to health practitioners
regarding the issues to implantable medical devices and advice
on how to manage such patients
• Product Defect Alert (new term) – undertaken for critical
therapeutic goods for which there is no alternative product or for
which a recall action will result in interruption of patient treatment or
a shortage
Post-market - Recalls and non-recall actions 4
Recall Classification – proposed changes
• a situation in which there is a reasonable
probability that the use of, or exposure to,
a deficient product will cause serious
adverse health consequences or death
Class
I
• a situation in which use of, or exposure to, a
deficient product may cause temporary or
medically reversible adverse health
consequences or where the probability of
serious adverse health consequences is remote
Class
II
• a situation in which use of, or exposure to, the
deficient product is not likely to cause adverse
health consequences
Class
III
Post-market - Recalls and non-recall actions 5
Legislative context
Schedule 3
Conformity assessment procedures
• Even though most recall
actions are initiated by the
manufacturer, such actions are
required under the medical
devices legislative framework
and are not voluntary
Post-market - Recalls and non-recall actions 6
Legislative Context (cont’d)
Section 41KA: Public notification
and recovery of medical devices
• The Secretary’s powers and
processes for mandating device
recalls not only for currently
‘included’ devices, but also for
exempt, cancelled or illegally
supplied devices
• Competition and Consumer Act
2010 (consumer goods)
– notification to ACCC for safety
related actions
Post-market - Recalls and non-recall actions 7
Responsibilities - manufacturers
• Has established recall procedures in
place to initiate a recall action
• Has established relationship with the
Australian Sponsor, including the ability
to quickly provide information when requested
• Identifies issues requiring recall or non-recall action
• Risk assessment (usually known as HHE/HHA)
• Identifies root cause and implements CAPA
• Have an effective QMS in place in accordance with
conformity assessment procedures (ISO 13485)
Post-market - Recalls and non-recall actions 8
Responsibilities – Sponsors
• Takes primary responsibility for implementing the recall action
(but can authorise third parties)
• Submits proposed communication strategy and draft letters to
the TGA
• Submits a risk assessment (HHE/HHA) undertaken by the
manufacturer for the issues identified
• Maintains product distribution details (and provides to the
TGA) to assist in facilitating a recall action
• Has established recall procedures in
place to undertake a recall action
• Reporting on the progress of the recall
action
Post-market - Recalls and non-recall actions 9
Responsibilities – TGA
• Undertakes independent review of risk
• Reviews recall strategy and correspondence and provides
agreement to initiation of recall action
• Advises stakeholders (primarily the state and territory health
departments) of recall actions including release of distribution
details to monitor the effectiveness of the recall
• Publication of all recalls in the SARA database
• TGA web statements for Hazard Alerts, consumer level and
sensitive recall actions
• Reviews root cause and CAPA and closes-out the recall action
Post-market - Recalls and non-recall actions 10
Follow-up reporting
The reporting requirements are:
• 2 and 6-week progress reports are required after the
commencement of the recall
• Close-out report requirements (usually 3 months or another
agreed timeframe):
• the results of the recall - quantity of stock returned,
outstanding etc.;
• the means of disposal, destruction or correction to the
recalled goods and confirmation that this has been
carried out; and
• details of the root cause analysis and
CAPA to prevent the problem from recurring.
Post-market - Recalls and non-recall actions 11
GS1 RecallNet Healthcare
The TGA does not require
sponsors to join GS1 RecallNet
Alternative method for notifying
the TGA of recall actions and
communicating with customers
who have been supplied
defective products
• The TGA provided advice to GS1 Australia on the
requirements and procedures outlined in the URPTG
• Has published a clarifying statement on the TGA website.
Post-market - Recalls and non-recall actions 12
What are they?
Recalls and associated actions are our “friends”
What are they?
Frequently painful
What are they?
• Ensure patients / users are protected / can effectively use
• Demonstrate our Manufacturers’ QMSs are working effectively
• Protect Company / Industry reputation
• Compliance is our responsibility
What are they?
Think what may happen if we didn’t
conduct Recalls…
What is the process?
Actively discuss with Recalls Unit
Pay close attention to what the
URPTG asks (and doesn’t ask) for
URPTG
• Is not legislation
“…an agreement between the therapeutic goods
industry and Commonwealth and State/Territory health
authorities.”
• As a Sponsor, you have to determine how to
comply
URPTG
• Information to be provided
• Details of the problem / product
• Risk Assessment and proposed action
• Type of hazard / assessment of risk
• Action / Classification / Level proposed
URPTG
• Availability of alternative product
New Product Defect Alert relevant here
• Have a focused approach
• provide the information necessary for
a successful outcome
• Importantly
• Collaborative process
• TGA will liaise with Sponsors and provide
advice and assistance
URPTG
• Confidentiality
• “It is recognised that some of the information provided may be of
a commercially sensitive or private nature and such information
will be treated appropriately.”
• Mark it as such if you think this is the case
• Some States / Territories may communicate widely on Recalls
• Issues with multiple communications and Recall returns
Types / Ways
• Depends on Classification and Level
• It’s a continuum:
• Class III with single / minimal customers
• Class I at the retail / consumer level
• With everything between
Types / Ways
• Hard copy / fax / e-mail – confirm receipt
• Receipt of acknowledgement forms
• GS1 RecallNet
Watch outs
• Liability?
• Coverage?
• Improvements into the future
• Requirement should be to Recall effectively
without specifying the medium
Manufacturer Responsibilities
An effective QMS that
• Maintains effective feedback
• Formalises evaluation methods
• Communicates and receives
inputs
Sponsor Responsibilities
• Requirement to report to TGA in a
timely fashion
• Established relationship with
manufacturer & TGA
• Best practice = written procedure
• Distribution records
• Quality holds
• Receive and action complaints
• Action the Recall and report
• 48 hours from approval
• 2 and 6 week reports,
with final closeout report
Questions
Post-market - Recalls and non-recall actions 26
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall actions

More Related Content

What's hot

Post Market Clinical Surveillance, Experience of the Industry by S. Menzl - ...
Post Market Clinical Surveillance,  Experience of the Industry by S. Menzl - ...Post Market Clinical Surveillance,  Experience of the Industry by S. Menzl - ...
Post Market Clinical Surveillance, Experience of the Industry by S. Menzl - ...
qserveconference2013
 

What's hot (20)

TGA presentation: medical devices audit assessments
TGA presentation: medical devices audit assessmentsTGA presentation: medical devices audit assessments
TGA presentation: medical devices audit assessments
 
TGA Presentation: Medical Devices - Manufacturer Evidence and applications fo...
TGA Presentation: Medical Devices - Manufacturer Evidence and applications fo...TGA Presentation: Medical Devices - Manufacturer Evidence and applications fo...
TGA Presentation: Medical Devices - Manufacturer Evidence and applications fo...
 
Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...
Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...
Device Sponsor Information Day: Session 4B: Medical Devices (IVDs) - applicat...
 
TGA presentation: Lifecycle of a Medical Device / IVD
TGA presentation: Lifecycle of a Medical Device / IVDTGA presentation: Lifecycle of a Medical Device / IVD
TGA presentation: Lifecycle of a Medical Device / IVD
 
Presentation: Conformity Assessment Evidence
Presentation: Conformity Assessment EvidencePresentation: Conformity Assessment Evidence
Presentation: Conformity Assessment Evidence
 
Presentation: Recall of Therapeutic Goods
Presentation: Recall of Therapeutic GoodsPresentation: Recall of Therapeutic Goods
Presentation: Recall of Therapeutic Goods
 
Presentation: Clinical Evidence Guidelines
Presentation: Clinical Evidence GuidelinesPresentation: Clinical Evidence Guidelines
Presentation: Clinical Evidence Guidelines
 
Sponsor Information and Training day Session A1 – Medical Devices: Efficient ...
Sponsor Information and Training day Session A1 – Medical Devices: Efficient ...Sponsor Information and Training day Session A1 – Medical Devices: Efficient ...
Sponsor Information and Training day Session A1 – Medical Devices: Efficient ...
 
Presentation: Medical Devices: how to stay included workshop - Annual Reports
Presentation: Medical Devices: how to stay included workshop - Annual ReportsPresentation: Medical Devices: how to stay included workshop - Annual Reports
Presentation: Medical Devices: how to stay included workshop - Annual Reports
 
Presentation: Medical Devices: how to stay included workshop - Post-market ro...
Presentation: Medical Devices: how to stay included workshop - Post-market ro...Presentation: Medical Devices: how to stay included workshop - Post-market ro...
Presentation: Medical Devices: how to stay included workshop - Post-market ro...
 
Presentation: Medical Devices: how to stay included workshop - Post-market re...
Presentation: Medical Devices: how to stay included workshop - Post-market re...Presentation: Medical Devices: how to stay included workshop - Post-market re...
Presentation: Medical Devices: how to stay included workshop - Post-market re...
 
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
 
Presentation: Manufacturing medical devices
Presentation: Manufacturing medical devicesPresentation: Manufacturing medical devices
Presentation: Manufacturing medical devices
 
Regulation of IVD medical devices - presentation at National Histotechnology ...
Regulation of IVD medical devices - presentation at National Histotechnology ...Regulation of IVD medical devices - presentation at National Histotechnology ...
Regulation of IVD medical devices - presentation at National Histotechnology ...
 
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
 
Presentation: Medical Devices: how to stay included workshop - Adverse event ...
Presentation: Medical Devices: how to stay included workshop - Adverse event ...Presentation: Medical Devices: how to stay included workshop - Adverse event ...
Presentation: Medical Devices: how to stay included workshop - Adverse event ...
 
Presentation: Life cycle of medical devices
Presentation: Life cycle of medical devicesPresentation: Life cycle of medical devices
Presentation: Life cycle of medical devices
 
Update on software as a medical device (SaMD)
Update on software as a medical device (SaMD)Update on software as a medical device (SaMD)
Update on software as a medical device (SaMD)
 
Post Market Clinical Surveillance, Experience of the Industry by S. Menzl - ...
Post Market Clinical Surveillance,  Experience of the Industry by S. Menzl - ...Post Market Clinical Surveillance,  Experience of the Industry by S. Menzl - ...
Post Market Clinical Surveillance, Experience of the Industry by S. Menzl - ...
 
TGA presentation: The role of the TGA
TGA presentation: The role of the TGATGA presentation: The role of the TGA
TGA presentation: The role of the TGA
 

Viewers also liked

MarkSandy-Resume
MarkSandy-ResumeMarkSandy-Resume
MarkSandy-Resume
Mark Sandy
 
Você S.A. | Fábio Nikel retorna à Senior como gerente de canais de distribuição
Você S.A. | Fábio Nikel retorna à Senior como gerente de canais de distribuiçãoVocê S.A. | Fábio Nikel retorna à Senior como gerente de canais de distribuição
Você S.A. | Fábio Nikel retorna à Senior como gerente de canais de distribuição
Senior Sistemas
 
Bab i desentralisasi
Bab i desentralisasiBab i desentralisasi
Bab i desentralisasi
Ara Vamps
 

Viewers also liked (11)

1
11
1
 
MarkSandy-Resume
MarkSandy-ResumeMarkSandy-Resume
MarkSandy-Resume
 
nicolas esguerra
nicolas esguerranicolas esguerra
nicolas esguerra
 
Rr revista
Rr revistaRr revista
Rr revista
 
Você S.A. | Fábio Nikel retorna à Senior como gerente de canais de distribuição
Você S.A. | Fábio Nikel retorna à Senior como gerente de canais de distribuiçãoVocê S.A. | Fábio Nikel retorna à Senior como gerente de canais de distribuição
Você S.A. | Fábio Nikel retorna à Senior como gerente de canais de distribuição
 
CV June 2015 Dxb
CV June 2015 DxbCV June 2015 Dxb
CV June 2015 Dxb
 
PADI Rescue Diver
PADI Rescue DiverPADI Rescue Diver
PADI Rescue Diver
 
Bab i desentralisasi
Bab i desentralisasiBab i desentralisasi
Bab i desentralisasi
 
Planning for Office 365 Mobile Access
Planning for Office 365 Mobile AccessPlanning for Office 365 Mobile Access
Planning for Office 365 Mobile Access
 
Ο ρόλος της Νορβηγίας στην συμφωνία του Όσλο το 1993
Ο ρόλος της Νορβηγίας στην συμφωνία του Όσλο το 1993Ο ρόλος της Νορβηγίας στην συμφωνία του Όσλο το 1993
Ο ρόλος της Νορβηγίας στην συμφωνία του Όσλο το 1993
 
Compos
ComposCompos
Compos
 

Similar to Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall actions

Recall procedures
Recall proceduresRecall procedures
Recall procedures
Syeda Abeer
 
Eu hot topics alliance presentation
Eu hot topics alliance presentationEu hot topics alliance presentation
Eu hot topics alliance presentation
Erik Vollebregt
 
Eu hot topics alliance presentation 3
Eu hot topics alliance presentation 3Eu hot topics alliance presentation 3
Eu hot topics alliance presentation 3
Erik Vollebregt
 
Eu hot topics alliance presentation 2
Eu hot topics alliance presentation 2Eu hot topics alliance presentation 2
Eu hot topics alliance presentation 2
Erik Vollebregt
 

Similar to Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall actions (20)

Sponsor Information and Training day Session A4 - Medical Devices: Recall and...
Sponsor Information and Training day Session A4 - Medical Devices: Recall and...Sponsor Information and Training day Session A4 - Medical Devices: Recall and...
Sponsor Information and Training day Session A4 - Medical Devices: Recall and...
 
Presentation Recall of Therapeutic Goods – Overview
Presentation Recall of Therapeutic Goods – Overview Presentation Recall of Therapeutic Goods – Overview
Presentation Recall of Therapeutic Goods – Overview
 
Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...
Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...
Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...
 
RECALL.pptx
RECALL.pptxRECALL.pptx
RECALL.pptx
 
Medicines and Medical Devices Regulation – current developments and future op...
Medicines and Medical Devices Regulation – current developments and future op...Medicines and Medical Devices Regulation – current developments and future op...
Medicines and Medical Devices Regulation – current developments and future op...
 
Prescription Medicines MMDR Reforms
Prescription Medicines MMDR ReformsPrescription Medicines MMDR Reforms
Prescription Medicines MMDR Reforms
 
Recall procedures
Recall proceduresRecall procedures
Recall procedures
 
Presentation: Increasing post-market vigilance requirements for medical devices
Presentation: Increasing post-market vigilance requirements for medical devicesPresentation: Increasing post-market vigilance requirements for medical devices
Presentation: Increasing post-market vigilance requirements for medical devices
 
Sponsor Information and Training day Session A3 - Medical Devices: Post-marke...
Sponsor Information and Training day Session A3 - Medical Devices: Post-marke...Sponsor Information and Training day Session A3 - Medical Devices: Post-marke...
Sponsor Information and Training day Session A3 - Medical Devices: Post-marke...
 
mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...
mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...
mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...
 
Unit 4 Complaints.pptx
Unit 4 Complaints.pptxUnit 4 Complaints.pptx
Unit 4 Complaints.pptx
 
Introduction to changes to the TGA's Clinical Trial Notification (CTN) process
Introduction to changes to the TGA's Clinical Trial Notification (CTN) processIntroduction to changes to the TGA's Clinical Trial Notification (CTN) process
Introduction to changes to the TGA's Clinical Trial Notification (CTN) process
 
The TGA Pharmacovigilance Inspection Pilot Program: 2015-2016
The TGA Pharmacovigilance Inspection Pilot Program: 2015-2016The TGA Pharmacovigilance Inspection Pilot Program: 2015-2016
The TGA Pharmacovigilance Inspection Pilot Program: 2015-2016
 
Eu hot topics alliance presentation
Eu hot topics alliance presentationEu hot topics alliance presentation
Eu hot topics alliance presentation
 
Eu hot topics alliance presentation 3
Eu hot topics alliance presentation 3Eu hot topics alliance presentation 3
Eu hot topics alliance presentation 3
 
Eu hot topics alliance presentation 2
Eu hot topics alliance presentation 2Eu hot topics alliance presentation 2
Eu hot topics alliance presentation 2
 
Complaints and recalls himanshu
Complaints and recalls himanshuComplaints and recalls himanshu
Complaints and recalls himanshu
 
Presentation: Regulatory affairs - The Australian and International landscape
Presentation: Regulatory affairs - The Australian and International landscapePresentation: Regulatory affairs - The Australian and International landscape
Presentation: Regulatory affairs - The Australian and International landscape
 
Sec. 15 Reporting Requirements, Corrective Action Plans, and Investigations
Sec. 15 Reporting Requirements, Corrective Action Plans, and InvestigationsSec. 15 Reporting Requirements, Corrective Action Plans, and Investigations
Sec. 15 Reporting Requirements, Corrective Action Plans, and Investigations
 
Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...
Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...
Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...
 

More from TGA Australia

More from TGA Australia (20)

Pharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsPharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirements
 
The challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devicesThe challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devices
 
Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch
 
Consumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI templateConsumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI template
 
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
 
Improved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future stateImproved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future state
 
Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...
 
Updates to Good Manufacturing Practices - Recent, current and future changes
Updates to Good Manufacturing Practices - Recent, current and future changesUpdates to Good Manufacturing Practices - Recent, current and future changes
Updates to Good Manufacturing Practices - Recent, current and future changes
 
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
 
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation Branch
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation Branch
 
Reporting of Medicine Shortages
Reporting of Medicine ShortagesReporting of Medicine Shortages
Reporting of Medicine Shortages
 
Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1
 
Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2
 
SME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory mazeSME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory maze
 
Presentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access BranchPresentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access Branch
 
Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...
 
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
 
Webinar presentation: Consultation on reforms to the generic medicine market ...
Webinar presentation: Consultation on reforms to the generic medicine market ...Webinar presentation: Consultation on reforms to the generic medicine market ...
Webinar presentation: Consultation on reforms to the generic medicine market ...
 

Recently uploaded

Female Call Girls Jodhpur Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Se...
Female Call Girls Jodhpur Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Se...Female Call Girls Jodhpur Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Se...
Female Call Girls Jodhpur Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Se...
Dipal Arora
 
Jual Obat Aborsi Di Dubai UAE Wa 0838-4800-7379 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi Di Dubai UAE Wa 0838-4800-7379 Obat Penggugur Kandungan CytotecJual Obat Aborsi Di Dubai UAE Wa 0838-4800-7379 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi Di Dubai UAE Wa 0838-4800-7379 Obat Penggugur Kandungan Cytotec
jualobat34
 
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Janvi Singh
 
Female Call Girls Sikar Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Serv...
Female Call Girls Sikar Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Serv...Female Call Girls Sikar Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Serv...
Female Call Girls Sikar Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Serv...
Dipal Arora
 
👉 Saharanpur Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl...
👉 Saharanpur Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl...👉 Saharanpur Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl...
👉 Saharanpur Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl...
chaddageeta79
 
Physiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdfPhysiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdf
MedicoseAcademics
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
MedicoseAcademics
 
👉 Gulbarga Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl S...
👉 Gulbarga Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl S...👉 Gulbarga Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl S...
👉 Gulbarga Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl S...
chaddageeta79
 

Recently uploaded (20)

Part I - Anticipatory Grief: Experiencing grief before the loss has happened
Part I - Anticipatory Grief: Experiencing grief before the loss has happenedPart I - Anticipatory Grief: Experiencing grief before the loss has happened
Part I - Anticipatory Grief: Experiencing grief before the loss has happened
 
Top 10 Most Beautiful Chinese Pornstars List 2024
Top 10 Most Beautiful Chinese Pornstars List 2024Top 10 Most Beautiful Chinese Pornstars List 2024
Top 10 Most Beautiful Chinese Pornstars List 2024
 
Female Call Girls Jodhpur Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Se...
Female Call Girls Jodhpur Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Se...Female Call Girls Jodhpur Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Se...
Female Call Girls Jodhpur Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Se...
 
Jual Obat Aborsi Di Dubai UAE Wa 0838-4800-7379 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi Di Dubai UAE Wa 0838-4800-7379 Obat Penggugur Kandungan CytotecJual Obat Aborsi Di Dubai UAE Wa 0838-4800-7379 Obat Penggugur Kandungan Cytotec
Jual Obat Aborsi Di Dubai UAE Wa 0838-4800-7379 Obat Penggugur Kandungan Cytotec
 
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
 
Shazia Iqbal 2024 - Bioorganic Chemistry.pdf
Shazia Iqbal 2024 - Bioorganic Chemistry.pdfShazia Iqbal 2024 - Bioorganic Chemistry.pdf
Shazia Iqbal 2024 - Bioorganic Chemistry.pdf
 
Premium Call Girls Jammu 🧿 7427069034 🧿 High Class Call Girl Service Available
Premium Call Girls Jammu 🧿 7427069034 🧿 High Class Call Girl Service AvailablePremium Call Girls Jammu 🧿 7427069034 🧿 High Class Call Girl Service Available
Premium Call Girls Jammu 🧿 7427069034 🧿 High Class Call Girl Service Available
 
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
 
Female Call Girls Sikar Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Serv...
Female Call Girls Sikar Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Serv...Female Call Girls Sikar Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Serv...
Female Call Girls Sikar Just Call Dipal 🥰8250077686🥰 Top Class Call Girl Serv...
 
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptx
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptxHISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptx
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptx
 
Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024
 
👉 Saharanpur Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl...
👉 Saharanpur Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl...👉 Saharanpur Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl...
👉 Saharanpur Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl...
 
Physicochemical properties (descriptors) in QSAR.pdf
Physicochemical properties (descriptors) in QSAR.pdfPhysicochemical properties (descriptors) in QSAR.pdf
Physicochemical properties (descriptors) in QSAR.pdf
 
Drug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptxDrug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptx
 
ABO Blood grouping in-compatibility in pregnancy
ABO Blood grouping in-compatibility in pregnancyABO Blood grouping in-compatibility in pregnancy
ABO Blood grouping in-compatibility in pregnancy
 
Physiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdfPhysiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdf
 
Call Now ☎ 9549551166 || Call Girls in Dehradun Escort Service Dehradun
Call Now ☎ 9549551166  || Call Girls in Dehradun Escort Service DehradunCall Now ☎ 9549551166  || Call Girls in Dehradun Escort Service Dehradun
Call Now ☎ 9549551166 || Call Girls in Dehradun Escort Service Dehradun
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
 
👉 Gulbarga Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl S...
👉 Gulbarga Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl S...👉 Gulbarga Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl S...
👉 Gulbarga Call Girls Service Just Call 🍑👄7427069034 🍑👄 Top Class Call Girl S...
 
Dr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdf
Dr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdfDr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdf
Dr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdf
 

Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall actions

  • 1. Post-market: recalls and non-recall actions Speakers ― Simon Waters Recalls Unit, Therapeutic Goods Administration Hugh Cameron Director Regulatory Affairs ANZ, Becton Dickinson
  • 2. Post-market Recalls and non-recall actions Simon Waters Recalls Unit Manufacturing Quality Branch Devices Sponsor Information Day 2015 15 October 2015
  • 3. The URPTG (current) 2004 edition Available online at http://www.tga.gov.au/pu blication/uniform-recall- procedure-therapeutic- goods-urptg Post-market - Recalls and non-recall actions 2
  • 4. Revised URPTG - proposed changes • Web based format – easy to navigate • Step-by-step protocol with supporting information • New/changes to recall terminologies • Risk classification – inclusion of probability aspects • Greater clarification on the requirements for medical devices (including IVDs) • Refined information required to assess a recall action Feedback from the public consultation will be considered before finalising the changes Post-market - Recalls and non-recall actions 3
  • 5. Recall actions – proposed changes The proposal is to have four types of recall actions: • Recall – the permanent removal of deficient goods from the market or from use • Recall for Product Defect Correction – repair, modification, adjustment, re-labelling, update to instructions or labelling • Hazard Alert – providing information to health practitioners regarding the issues to implantable medical devices and advice on how to manage such patients • Product Defect Alert (new term) – undertaken for critical therapeutic goods for which there is no alternative product or for which a recall action will result in interruption of patient treatment or a shortage Post-market - Recalls and non-recall actions 4
  • 6. Recall Classification – proposed changes • a situation in which there is a reasonable probability that the use of, or exposure to, a deficient product will cause serious adverse health consequences or death Class I • a situation in which use of, or exposure to, a deficient product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote Class II • a situation in which use of, or exposure to, the deficient product is not likely to cause adverse health consequences Class III Post-market - Recalls and non-recall actions 5
  • 7. Legislative context Schedule 3 Conformity assessment procedures • Even though most recall actions are initiated by the manufacturer, such actions are required under the medical devices legislative framework and are not voluntary Post-market - Recalls and non-recall actions 6
  • 8. Legislative Context (cont’d) Section 41KA: Public notification and recovery of medical devices • The Secretary’s powers and processes for mandating device recalls not only for currently ‘included’ devices, but also for exempt, cancelled or illegally supplied devices • Competition and Consumer Act 2010 (consumer goods) – notification to ACCC for safety related actions Post-market - Recalls and non-recall actions 7
  • 9. Responsibilities - manufacturers • Has established recall procedures in place to initiate a recall action • Has established relationship with the Australian Sponsor, including the ability to quickly provide information when requested • Identifies issues requiring recall or non-recall action • Risk assessment (usually known as HHE/HHA) • Identifies root cause and implements CAPA • Have an effective QMS in place in accordance with conformity assessment procedures (ISO 13485) Post-market - Recalls and non-recall actions 8
  • 10. Responsibilities – Sponsors • Takes primary responsibility for implementing the recall action (but can authorise third parties) • Submits proposed communication strategy and draft letters to the TGA • Submits a risk assessment (HHE/HHA) undertaken by the manufacturer for the issues identified • Maintains product distribution details (and provides to the TGA) to assist in facilitating a recall action • Has established recall procedures in place to undertake a recall action • Reporting on the progress of the recall action Post-market - Recalls and non-recall actions 9
  • 11. Responsibilities – TGA • Undertakes independent review of risk • Reviews recall strategy and correspondence and provides agreement to initiation of recall action • Advises stakeholders (primarily the state and territory health departments) of recall actions including release of distribution details to monitor the effectiveness of the recall • Publication of all recalls in the SARA database • TGA web statements for Hazard Alerts, consumer level and sensitive recall actions • Reviews root cause and CAPA and closes-out the recall action Post-market - Recalls and non-recall actions 10
  • 12. Follow-up reporting The reporting requirements are: • 2 and 6-week progress reports are required after the commencement of the recall • Close-out report requirements (usually 3 months or another agreed timeframe): • the results of the recall - quantity of stock returned, outstanding etc.; • the means of disposal, destruction or correction to the recalled goods and confirmation that this has been carried out; and • details of the root cause analysis and CAPA to prevent the problem from recurring. Post-market - Recalls and non-recall actions 11
  • 13. GS1 RecallNet Healthcare The TGA does not require sponsors to join GS1 RecallNet Alternative method for notifying the TGA of recall actions and communicating with customers who have been supplied defective products • The TGA provided advice to GS1 Australia on the requirements and procedures outlined in the URPTG • Has published a clarifying statement on the TGA website. Post-market - Recalls and non-recall actions 12
  • 14. What are they? Recalls and associated actions are our “friends”
  • 16. What are they? • Ensure patients / users are protected / can effectively use • Demonstrate our Manufacturers’ QMSs are working effectively • Protect Company / Industry reputation • Compliance is our responsibility
  • 17. What are they? Think what may happen if we didn’t conduct Recalls…
  • 18. What is the process? Actively discuss with Recalls Unit Pay close attention to what the URPTG asks (and doesn’t ask) for
  • 19. URPTG • Is not legislation “…an agreement between the therapeutic goods industry and Commonwealth and State/Territory health authorities.” • As a Sponsor, you have to determine how to comply
  • 20. URPTG • Information to be provided • Details of the problem / product • Risk Assessment and proposed action • Type of hazard / assessment of risk • Action / Classification / Level proposed
  • 21. URPTG • Availability of alternative product New Product Defect Alert relevant here • Have a focused approach • provide the information necessary for a successful outcome • Importantly • Collaborative process • TGA will liaise with Sponsors and provide advice and assistance
  • 22. URPTG • Confidentiality • “It is recognised that some of the information provided may be of a commercially sensitive or private nature and such information will be treated appropriately.” • Mark it as such if you think this is the case • Some States / Territories may communicate widely on Recalls • Issues with multiple communications and Recall returns
  • 23. Types / Ways • Depends on Classification and Level • It’s a continuum: • Class III with single / minimal customers • Class I at the retail / consumer level • With everything between
  • 24. Types / Ways • Hard copy / fax / e-mail – confirm receipt • Receipt of acknowledgement forms • GS1 RecallNet Watch outs • Liability? • Coverage? • Improvements into the future • Requirement should be to Recall effectively without specifying the medium
  • 25. Manufacturer Responsibilities An effective QMS that • Maintains effective feedback • Formalises evaluation methods • Communicates and receives inputs
  • 26. Sponsor Responsibilities • Requirement to report to TGA in a timely fashion • Established relationship with manufacturer & TGA • Best practice = written procedure • Distribution records • Quality holds • Receive and action complaints • Action the Recall and report • 48 hours from approval • 2 and 6 week reports, with final closeout report
  • 27. Questions Post-market - Recalls and non-recall actions 26